In November, many pharmaceutical companies achieved new breakthroughs in the field of antibiotics

Antibiotics are a class of secondary metabolites produced by microorganisms (including bacteria, fungi, and actinomycetes) or higher animals and plants during their lives that have anti-pathogen or other activities and can interfere with the development of other living cells.

.
Analysts pointed out that with the acceleration of China's population aging process and the expansion of national medical insurance investment, the antibiotic industry as a whole will still maintain a large demand in the next few years.
It is expected that the market size of China's antibiotic industry will be close to 1.
950 billion yuan by 2022
.
As one of the commonly used drugs, antibiotics have a large domestic market, which has attracted many companies such as Kelun Pharmaceuticals in Sichuan, Fuxiang Pharmaceuticals in Jiangxi, and Lukang Pharmaceuticals in Shandong
.
With the advancement of enterprises, the output of antibiotics continues to rise, and the types continue to grow
.
It is understood that in November, many pharmaceutical companies have achieved new breakthroughs in the field of antibiotics
.
For example, on November 29, Huadong Medicine issued an announcement that the new drug application for daptomycin for injection declared by its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co.
, Ltd.
to the U.
S.
Food and Drug Administration (FDA) was approved
.
According to the industry, the approval of daptomycin for injection in the United States is another freeze-dried powder injection approved by Huadong Medicine after pantoprazole sodium for injection.
Market-approved daptomycin preparation product
.
The announcement showed that Daptomycin belongs to the cycloaliphatic peptide antibiotic, a super antibiotic product, used to treat complex skin and soft tissue infections (cSSSI), Staphylococcus aureus bloodstream infection (bacteremia) and Concomitant infective endocarditis on the right side
.
According to the announcement, the daptomycin for injection developed by Sino-US East China was approved for listing in China in 2015 and is an important product in the company's anti-infective drug treatment field
.
According to data, the sales of daptomycin for injection in the domestic market in 2020 is about 130 million yuan, of which Sino-US East China’s domestic market share is about 36%
.
In addition, on November 18, the State Food and Drug Administration issued 76 drug approval documents pending information, among which Zhejiang Hisun Pharmaceutical’s vancomycin hydrochloride for injection was among them, and the supplementary application for consistency evaluation submitted by Zhejiang Hisun Pharmaceutical was approved.
Become the second company that has been evaluated for this variety
.
According to data, vancomycin is the first glycopeptide antibiotic to come out.
The original research was developed by Eli Lilly.
It has bactericidal activity against a variety of Gram-positive bacteria and is a drug for the treatment of MRSA infections
.
In recent years, the Chinese market has continued to expand steadily.
In 2020, the product has achieved 1.
4 billion in-hospital sales.
In the first half of 2021, sales increased by 72% year-on-year to over 900 million yuan
.
At present, there are still 7 domestic companies approved to produce vancomycin-related preparations, including 2 import companies and 5 domestic pharmaceutical companies
.
The five domestic companies are Zhejiang Pharmaceutical, Livzon Group, Zhejiang Hisun Pharmaceutical, North China Pharmaceutical, and Zhejiang Zhebei Pharmaceutical
.
At present, only Zhejiang Pharmaceutical and Zhejiang Hisun Pharmaceutical have submitted supplementary applications for consistency evaluation
.
Among them, Zhejiang Medicine was approved in June 2021 and won the first review of vancomycin hydrochloride for injection
.
This time, Zhejiang Hisun Pharmaceutical is the second company that has been evaluated for this product
.
It is understood that in recent years, under the implementation of antimicrobial control measures such as the graded management of antibiotics in China, the antibiotic market has grown slowly.
By 2020, the market size of China's antibiotic industry will reach 178 billion yuan
.
However, in the next few years, with the increasing aging of the domestic population and the expansion of national medical insurance investment, the antibiotic industry as a whole will maintain a large demand.
It is estimated that by 2022, the market size of China's antibiotic industry may approach 1.
950 billion yuan
.